KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Debt to Equity (2016 - 2024)

Biomarin Pharmaceutical (BMRN) has disclosed Debt to Equity for 12 consecutive years, with $0.09 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Debt to Equity changed N/A year-over-year to $0.09, compared with a TTM value of $0.09 through Jun 2024, changed N/A, and an annual FY2023 reading of $0.1, changed N/A over the prior year.
  • Debt to Equity was $0.09 for Q2 2024 at Biomarin Pharmaceutical, down from $0.1 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.1 in Q3 2023 and bottomed at $0.01 in Q3 2022.
  • Average Debt to Equity over 5 years is $0.05, with a median of $0.01 recorded in 2022.
  • The sharpest move saw Debt to Equity soared 2738.55% in 2020, then tumbled 87.75% in 2021.
  • Year by year, Debt to Equity stood at $0.09 in 2020, then plummeted by 87.75% to $0.01 in 2021, then crashed by 45.21% to $0.01 in 2022, then surged by 1509.98% to $0.1 in 2023, then dropped by 6.15% to $0.09 in 2024.
  • Business Quant data shows Debt to Equity for BMRN at $0.09 in Q2 2024, $0.1 in Q1 2024, and $0.1 in Q4 2023.